GLP-1 receptor agonist slows Alzheimer’s cognitive decline
In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia.
In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language and decision-making by nearly 50% compared to placebo.
The trial data was reported at the Alzheimer’s Association International Conference (AAIC) 2024, in Philadelphia, US.
GLP-1 receptor agonists have already been shown to help people manage diabetes, lose weight and lower their risk of heart disease, stroke and kidney disease.
Research in animal models of Alzheimer’s disease suggests these drugs may have neuroprotective effects, reduce early forms of amyloid, normalise the brain’s processing of glucose, and improve memory and learning.
This new research suggests liraglutide may protect the brains of people with mild Alzheimer’s disease and reduce cognitive decline by as much as 18% after one year of treatment compared to placebo.
“We are in an era of unprecedented promise, with new treatments in various stages of development that slow or may possibly prevent cognitive decline due to Alzheimer’s disease,” said Maria Carrillo, Alzheimer’s Association Chief Science Officer and Medical Affairs Lead. “This research provides hope that more options for changing the course of the disease are on the horizon.
“Repurposing drugs already approved for other conditions has the advantage of providing data and experience from previous research and practical use – so we already know a lot about real-world effectiveness in other diseases and side effects.”
The Alzheimer’s Association Part the Cloud research grants programme has invested more than $82 million to advance 68 clinical trials.
Liraglutide protects the brain
The recent trial was led by Professor Paul Edison, Professor of Science from Imperial College London, and included 204 patients with mild Alzheimer’s disease seen at 24 clinics throughout the UK.
The study’s primary endpoint was change in the cerebral glucose metabolic rate in the cortical regions of the brain (hippocampus, medial temporal lobe and posterior cingulate), which was not met. However, the secondary endpoint of change in scores for clinical and cognitive measures and the exploratory endpoint of brain volume showed statistically significant benefit.
“The slower loss of brain volume suggests liraglutide protects the brain, much like statins protect the heart,” said Professor Edison. “While further research is needed, liraglutide may work through various mechanisms, such as reducing inflammation in the brain, lowering insulin resistance and the toxic effects of Alzheimer’s biomarkers amyloid-beta and tau, and improving how the brain’s nerve cells communicate.”
Those in the study who received liraglutide had nearly 50% less volume loss in several areas of the brain, including frontal, temporal, parietal and total grey matter, as measured by MRI.
Diana Spencer, Senior Digital Content Editor, DDW
